These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

507 related items for PubMed ID: 18309230

  • 1. Prediction of Alzheimer's disease using a cerebrospinal fluid pattern of C-terminally truncated beta-amyloid peptides.
    Höglund K, Hansson O, Buchhave P, Zetterberg H, Lewczuk P, Londos E, Blennow K, Minthon L, Wiltfang J.
    Neurodegener Dis; 2008; 5(5):268-76. PubMed ID: 18309230
    [Abstract] [Full Text] [Related]

  • 2. Value of CSF beta-amyloid1-42 and tau as predictors of Alzheimer's disease in patients with mild cognitive impairment.
    Hampel H, Teipel SJ, Fuchsberger T, Andreasen N, Wiltfang J, Otto M, Shen Y, Dodel R, Du Y, Farlow M, Möller HJ, Blennow K, Buerger K.
    Mol Psychiatry; 2004 Jul; 9(7):705-10. PubMed ID: 14699432
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Evaluation of plasma Abeta(40) and Abeta(42) as predictors of conversion to Alzheimer's disease in patients with mild cognitive impairment.
    Hansson O, Zetterberg H, Vanmechelen E, Vanderstichele H, Andreasson U, Londos E, Wallin A, Minthon L, Blennow K.
    Neurobiol Aging; 2010 Mar; 31(3):357-67. PubMed ID: 18486992
    [Abstract] [Full Text] [Related]

  • 5. Diagnosing prodromal Alzheimer's disease: role of CSF biochemical markers.
    Parnetti L, Lanari A, Silvestrelli G, Saggese E, Reboldi P.
    Mech Ageing Dev; 2006 Feb; 127(2):129-32. PubMed ID: 16274728
    [Abstract] [Full Text] [Related]

  • 6. Prediction of Alzheimer's disease using the CSF Abeta42/Abeta40 ratio in patients with mild cognitive impairment.
    Hansson O, Zetterberg H, Buchhave P, Andreasson U, Londos E, Minthon L, Blennow K.
    Dement Geriatr Cogn Disord; 2007 Feb; 23(5):316-20. PubMed ID: 17374949
    [Abstract] [Full Text] [Related]

  • 7. Anomalously phosphorylated tau and Abeta fragments in the CSF correlates with cognitive impairment in MCI subjects.
    Maccioni RB, Lavados M, Guillón M, Mujica C, Bosch R, Farías G, Fuentes P.
    Neurobiol Aging; 2006 Feb; 27(2):237-44. PubMed ID: 16399209
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Episodic memory and speed/attention deficits are associated with Alzheimer-typical CSF abnormalities in MCI.
    Nordlund A, Rolstad S, Klang O, Lind K, Pedersen M, Blennow K, Edman A, Hansen S, Wallin A.
    J Int Neuropsychol Soc; 2008 Jul; 14(4):582-90. PubMed ID: 18577287
    [Abstract] [Full Text] [Related]

  • 10. Multiplexed quantification of dementia biomarkers in the CSF of patients with early dementias and MCI: a multicenter study.
    Lewczuk P, Kornhuber J, Vanderstichele H, Vanmechelen E, Esselmann H, Bibl M, Wolf S, Otto M, Reulbach U, Kölsch H, Jessen F, Schröder J, Schönknecht P, Hampel H, Peters O, Weimer E, Perneczky R, Jahn H, Luckhaus C, Lamla U, Supprian T, Maler JM, Wiltfang J.
    Neurobiol Aging; 2008 Jun; 29(6):812-8. PubMed ID: 17239996
    [Abstract] [Full Text] [Related]

  • 11. Cerebrospinal fluid biomarkers for Alzheimer’s disease: diagnostic performance in a homogeneous mono-center population.
    Johansson P, Mattsson N, Hansson O, Wallin A, Johansson JO, Andreasson U, Zetterberg H, Blennow K, Svensson J.
    J Alzheimers Dis; 2011 Jun; 24(3):537-46. PubMed ID: 21297262
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Cystatin C levels are positively correlated with both Abeta42 and tau levels in cerebrospinal fluid in persons with Alzheimer's disease, mild cognitive impairment, and healthy controls.
    Sundelöf J, Sundström J, Hansson O, Eriksdotter-Jönhagen M, Giedraitis V, Larsson A, Degerman-Gunnarsson M, Ingelsson M, Minthon L, Blennow K, Kilander L, Basun H, Lannfelt L.
    J Alzheimers Dis; 2010 Jun; 21(2):471-8. PubMed ID: 20555147
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. CSF beta-amyloid 1-42 and tau in Tunisian patients with Alzheimer's disease: the effect of APOE epsilon4 allele.
    Smach MA, Charfeddine B, Lammouchi T, Harrabi I, Ben Othman L, Dridi H, Bennamou S, Limem K.
    Neurosci Lett; 2008 Aug 01; 440(2):145-9. PubMed ID: 18555606
    [Abstract] [Full Text] [Related]

  • 17. Cerebrospinal fluid beta-amyloid1-42 and tau in control subjects at risk for Alzheimer's disease: the effect of APOE epsilon4 allele.
    Sunderland T, Mirza N, Putnam KT, Linker G, Bhupali D, Durham R, Soares H, Kimmel L, Friedman D, Bergeson J, Csako G, Levy JA, Bartko JJ, Cohen RM.
    Biol Psychiatry; 2004 Nov 01; 56(9):670-6. PubMed ID: 15522251
    [Abstract] [Full Text] [Related]

  • 18. CSF biomarkers predict rate of cognitive decline in Alzheimer disease.
    Kester MI, van der Vlies AE, Blankenstein MA, Pijnenburg YA, van Elk EJ, Scheltens P, van der Flier WM.
    Neurology; 2009 Oct 27; 73(17):1353-8. PubMed ID: 19858456
    [Abstract] [Full Text] [Related]

  • 19. CSF Abeta42, Tau and phosphorylated Tau, APOE epsilon4 allele and MCI type in progressive MCI.
    Herukka SK, Helisalmi S, Hallikainen M, Tervo S, Soininen H, Pirttilä T.
    Neurobiol Aging; 2007 Apr 27; 28(4):507-14. PubMed ID: 16546302
    [Abstract] [Full Text] [Related]

  • 20. Cerebrospinal fluid amyloid beta(1-42) levels in the mild cognitive impairment stage of Alzheimer's disease.
    Maruyama M, Arai H, Sugita M, Tanji H, Higuchi M, Okamura N, Matsui T, Higuchi S, Matsushita S, Yoshida H, Sasaki H.
    Exp Neurol; 2001 Dec 27; 172(2):433-6. PubMed ID: 11716567
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.